

Date: 29<sup>th</sup> December, 2022

From :  
Mitaben B. Chokshi  
(Member of Promoter Group of Arvee Laboratories ( India ) Limited )

To, Company Secretary Arvee Laboratories ( India ) Limited 403, Entice Building, Nr. Jayantilal Park, BRTS, Bopal Ambli Road, Ahmedabad ( By Email at <a href="mailto:compliance@arveelabs.com">compliance@arveelabs.com</a>	To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra ( E ), Mumbai - 400 051 ( By Email at <a href="mailto:takeover@nse.co.in">takeover@nse.co.in</a> )
---	---

Scrip Code : ARVEE

Sub : Report under Regulation 10 ( 6 ) of Securities and Exchange Board of India ( Substantial Acquisition of Shares and Takeovers ) Regulations, 2011

Reference: Prior Intimation filed under Regulation 10(5) submitted to the Exchange on 17.12.2022

Dear Sir / Madam,

In compliance with the provisions of Regulation 10(6) of SEBI (SAST) Regulations, 2011, the undersigned being part of the Promoters Group of the Company, hereby furnish the report in the specified format under regulation 10(6) in respect of post inter - se acquisition of 6,69,000 ( 6.07 % ) of Arvee Laboratories ( India ) Limited being the Target Company (TC) in the following manner.

1. Inter-se transfer of 6,69,000 Equity Shares from Saumil Bharatbhai Chokshi constituting 6.07% of total capital to mother namely Mitaben B. Chokshi.

The shares have been acquired in lieu of private family arrangement amongst the immediate relatives and members of Promoters Group by way of gift pursuant to Regulation 10(1)(a)(i) of SEBI (SAST) Regulations, 2011 and there has been no change in the aggregate total shareholding of the Promoters and Promoters Group after said acquisition.

Thanking You

X *M B Chokshi*  
Mitaben B. Chokshi

( Member of Promoter Group of Arvee Laboratories ( India ) Limited )  
Copy to :

Securities and Exchange Board of India By way of Email at  
[sastexemptionapplication@sebi.gov.in](mailto:sastexemptionapplication@sebi.gov.in)

Encl : As Above

Format for Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	Name of the Target Company (TC)	ARVEE LABORATORIES (INDIA ) LIMITED	
2	Name of the acquirer(s)	The disclosure is pursuant to inter-se transfer of shares amongst immediate relatives and members of the Promoter Group. The Transferee(s)/ Acquirer(s) are ( i ) Mitaben B. Chokshi	
3	Name of the stock exchange where shares of the TC are listed	National Stock Exchange of India Limited	
4	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Date of Transaction : 27.12.2022  Inter-se Transfer of Shares as a gift amongst immediate relatives and members of Promoters Group as a part of family arrangement.	
5	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10 ( 1 ) ( a ) ( i )	
6	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange	Yes. Disclosure under Regulation 10 ( 5 ) was made within the time line specified under Regulation  Letter dated 16 <sup>th</sup> December, 2022 which was mailed on 17 <sup>th</sup> December, 2022	
7	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
	a. Name of the transferor / seller	Saumil Bharat Chokshi	Yes
	b. Date of acquisition / transfer	27.12.2022	
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a)	( i ) Mitaben B. Chokshi acquired 6,69,000 Equity Shares from Saumil Bharat Chokshi constituting 6.07% of total Capital.	

X Mitaben B. Chokshi

